A prospective trial of treating patients with nasopharyngeal carcinoma in late stage by combined hyperfractionated radiotherapy and concurrent chemotherapyJournal of Xi'an Jiaotong University (Medical Sciences)
AbstractObjective: To evaluate the therapeutic effect and reactions of hyperfractionated radiotherapy combined with concurrent chemotherapy for nasopharyngeal carcinoma (NPC) in stages III and IV. Methods: Sixty previously untreated NPC patients were randomly assigned to hyperfractionated radiotherapy plus chemotherapy (experimental group) and hyperfractionated radiotherapy (control group). Irradiation dose to the NPC foci were: experimental group 1.2 Gy/f, 2f/d, to a total dose of 75.5 Gy; for neck nodes: 79 Gy to patients with positive nodes. PFL was used in chemotherapy regimen: PDD: 60 mgÂ·m -2, d1; 5-FU 750 mgÂ·m-2, d2~4, Lv 100 mgÂ·m-2, d2~4, q4w. Results: The experimental group had a higher complete regression rate of tumor and a higher 1, 3 and 5 year survival rate than the control group (P < 0.05), but it had more serious irradiation reactions than the control group (P < 0.05). Conclusion: Hyperfractionated radiotherapy plus chemotherapy has better therapeutic effects with tolerable reactions. Therefore, combination of hyperfractionated radiotherapy with chemotherapy regimen for NPC patients seems justified.
Citation InformationH. Deng, X. Zhang, Qian Chen and S Han. "A prospective trial of treating patients with nasopharyngeal carcinoma in late stage by combined hyperfractionated radiotherapy and concurrent chemotherapy" Journal of Xi'an Jiaotong University (Medical Sciences) Vol. 24 Iss. 4 (2003) p. 387 - 389
Available at: http://works.bepress.com/qian_chen/31/